Xilio Therapeutics has raised $95 million to take IL-2 and CTLA-4 immunotherapies into clinical trials. The series C positions Xilio to provide early clinical validation of anti-cancer agents that are designed to remain inactive until they reach tumors.
French Big Pharma Sanofi is teaming up with Germany’s Sirion Biotech for its viral-vector-based gene delivery tech.
Brainlab has secured two FDA clearances for its robotic surgery systems, including an articulated arm for guiding spine procedures and an autonomously mobile imaging robot.
Combining immuno-oncology treatments like checkpoint inhibitors with other cancer-killing drugs is considered to be a key strategy for improving the response rate to immunotherapy. Now, a team of Canadian researchers is suggesting a new combination strategy for improving the response of the immune system’s T cells to immuno-oncology drugs, and it involves epigenetics.
A phase 3 clinical trial of Otonomy’s Otividex in inner ear condition Ménière’s disease has missed its primary endpoint. The setback comes almost four years after the generation of mixed data from two earlier phase 3 studies persuaded Otonomy to roll the dice on another pivotal clinical trial.
Breaking Big Pharma’s AI barrier: Insilico Medicine uncovers novel target, new drug for pulmonary fibrosis in 18 months
For years, artificial intelligence has promised to shave months, if not years, off the total amount of time needed to develop a brand-new drug—and for potentially millions of dollars less, to boot. But by exactly how much has typically been left up to the imagination, though perhaps coming into clearer focus with each occasional breakthrough.
The FDA has approved its first 3D-printed metal implant designed to replace the main bone in the ankle joint connecting the leg to the foot.
Dermavant Sciences has linked its plaque psoriasis prospect tapinarof to deepening improvements in outcomes over the first year of treatment. The number of responders rose in an interim analysis of a 40-week extension study, which followed successful phase 3 clinical trials that read out last year.
Eli Lilly has penned a research and sales pact with Rigel Pharmaceuticals for its experimental med R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor.
In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.